Beneficial therapeutic effects of hemoperfusion in the treatment of severe @entity6715 / XXXX : preliminary results.

@entity1 @entity137 @entity6715 @entity203 @entity299 @entity272 @entity715 @entity551
OBJECTIVE: Most of @entity6715 ( @entity6715 ) and @entity137 ( @entity137 ) are severe @entity203 . There is currently no established treatment due to a lack of controlled/blinded studies. High-dose glucocorticoids and intravenous immunoglobulins (IVIG) therapy have been widely used, but these approaches remain controversial. This study introduces a novel method by which to treat severe @entity6715 / @entity137 @entity1 who were refractory to glucocorticoids and IVIG. @entity1 AND METHODS: Seven @entity1 with @entity6715 and three @entity1 with @entity137 were enrolled in this non-blinded, uncontrolled study. The average @entity1 age was 8.1 years. The male to female ratio was 1:1. Hemoperfusion was conducted daily using a HA280 resin sorbent column until new @entity272 ceased appearing and the skin started healing with visible re-epithelialization. RESULTS: The average BSA involvement in @entity6715 and @entity137 was 8.57% and 75%, respectively. The number of hemoperfusion sessions ranged from 3 to 5. Hemoperfusion led to prompt improvements in general health and halted the disease progression. All @entity1 were discharged and recovered completely. The average length of stay was 14.4 days. Four @entity1 experienced adverse reactions: femoral vein @entity715 (N = 2), @entity551 (N = 1), and @entity299 (N = 1). CONCLUSIONS: Hemoperfusion may be a useful adjunct treatment for @entity1 with severe @entity6715 / @entity137 if the initial treatment with glucocorticoids and IVIG fails.
